Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients

References

• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–12. doi:10.1038/nature11404.
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–1075. doi:10.1038/nature07423.
   PubMed Web of Science ®Google Scholar
• Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh T, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–1120. doi:10.1016/j.cell.2012.08.029.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, Kang B, Liu Z, Jin L, Xing R, et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018;24(7):978–985. doi:10.1038/s41591-018-0045-3.
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, Amir EAD, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–765.e17. doi:10.1016/j.cell.2017.04.014.
   PubMed Web of Science ®Google Scholar
• Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria J-C, Barlesi F, et al. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. J Immunother Cancer. 2022;10(5):e003890. doi:10.1136/jitc-2021-003890.
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499–514. doi:10.1038/s41571-022-00639-9.
   PubMed Web of Science ®Google Scholar
• Yang CY, Yang JC, Yang PC. Precision management of advanced non–small cell lung cancer. Annu Rev Med. 2020;71(1):117–136. doi:10.1146/annurev-med-051718-013524.
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction Targeted Ther. 2019;4(1):61. doi:10.1038/s41392-019-0099-9.
   PubMedGoogle Scholar
• Ye L, Creaney J, Redwood A, Robinson B. The Current lung cancer neoantigen landscape and implications for therapy. J Thorac Oncol. 2021;16(6):922–932. doi:10.1016/j.jtho.2021.01.1624.
   PubMed Web of Science ®Google Scholar
• Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625–644. doi:10.1038/s41571-021-00520-1.
   PubMed Web of Science ®Google Scholar
• Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–557. doi:10.1038/s41571-021-00501-4.
   PubMed Web of Science ®Google Scholar
• Chiang AC, Herbst RS. Frontline immunotherapy for NSCLC - the tale of the tail. Nat Rev Clin Oncol. 2020;17(2):73–74. doi:10.1038/s41571-019-0317-y.
   PubMed Web of Science ®Google Scholar
• Iams WT, Porter J, Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300–312. doi:10.1038/s41571-019-0316-z.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019;29(10):846–861. doi:10.1038/s41422-019-0224-x.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–472. doi:10.1016/j.ccell.2015.02.015.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119. doi:10.1038/s41590-017-0022-x.
   PubMed Web of Science ®Google Scholar
• Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150. doi:10.1038/ncomms12150.
   PubMed Web of Science ®Google Scholar
• Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 2015;125(9):3365–3376. doi:10.1172/JCI80006.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268. doi:10.1038/nri3175.
   PubMed Web of Science ®Google Scholar
• De Sanctis F, Solito S, Ugel S, Molon B, Bronte V, Marigo I. Mdscs in cancer: Conceiving new prognostic and therapeutic targets. Biochim Biophys Acta. 2016;1865(1):35–48. doi:10.1016/j.bbcan.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. doi:10.1038/s41416-018-0333-1.
   PubMed Web of Science ®Google Scholar
• Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641–654. doi:10.1038/nri1668.
   PubMed Web of Science ®Google Scholar
• Hofer F, Di Sario G, Musiu C, Sartoris S, De Sanctis F, Ugel S. A complex metabolic network confers immunosuppressive functions to myeloid-derived suppressor cells (MDSCs) within the tumour microenvironment. Cells. 2021;10(10):2700. doi:10.3390/cells10102700.
   PubMed Web of Science ®Google Scholar
• Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498. doi:10.1038/s41577-020-00490-y.
   PubMed Web of Science ®Google Scholar
• Trovato R, Cane S, Petrova V, Sartoris S, Ugel S, De Sanctis F. The engagement between MDSCs and metastases: Partners in crime. Front Oncol. 2020;10:165. doi:10.3389/fonc.2020.00165.
   PubMed Web of Science ®Google Scholar
• Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann NY Acad Sci. 2014;1319(1):47–65. doi:10.1111/nyas.12469.
   PubMed Web of Science ®Google Scholar
• Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid cells as clinical biomarkers for immune checkpoint blockade. Front Immunol. 2020;11:1590. doi:10.3389/fimmu.2020.01590.
   PubMed Web of Science ®Google Scholar
• Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310. doi:10.3389/fimmu.2018.01310.
   PubMed Web of Science ®Google Scholar
• Grover A, Sanseviero E, Timosenko E, Gabrilovich DI. Myeloid-derived suppressor cells: A propitious road to clinic. Cancer Discov. 2021;11(11):2693–2706. doi:10.1158/2159-8290.CD-21-0764.
   PubMed Web of Science ®Google Scholar
• Haverkamp JM, Smith AM, Weinlich R, Dillon C, Qualls J, Neale G, Koss B, Kim Y, Bronte V, Herold M, et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014;41(6):947–959. doi:10.1016/j.immuni.2014.10.020.
   PubMed Web of Science ®Google Scholar
• Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, et al. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun. 2018;9(1):5193. doi:10.1038/s41467-018-07654-4.
   PubMedGoogle Scholar
• Musiu C, Caligola S, Fiore A, Lamolinara A, Frusteri C, Del Pizzo FD, De Sanctis F, Canè S, Adamo A, Hofer F, et al. Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. Cell Death Differ. 2022;29(2):420–438. doi:10.1038/s41418-021-00866-0.
   PubMed Web of Science ®Google Scholar
• Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, Blosser RL, Tam AJ, Bruno T, Zhang H, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123(4):1580–1589. doi:10.1172/JCI60083.
   PubMed Web of Science ®Google Scholar
• Trovato R, Fiore A, Sartori S, Canè S, Giugno R, Cascione L, Paiella S, Salvia R, De Sanctis F, Poffe O, et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer. 2019;7(1):255. doi:10.1186/s40425-019-0734-6.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8(1):e000398. doi:10.1136/jitc-2019-000398.
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, et al. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021;32(12):1597–1607. doi:10.1016/j.annonc.2021.08.2151.
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee B-N, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97(1):256–263. doi:10.1182/blood.V97.1.256.
   PubMed Web of Science ®Google Scholar
• Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–6416. doi:10.1172/JCI141772.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334. doi:10.1001/jama.286.3.327.
   PubMed Web of Science ®Google Scholar
• Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, Longatto-Filho A. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS One. 2017;12(7):e0181125. doi:10.1371/journal.pone.0181125.
   PubMed Web of Science ®Google Scholar
• O’Neill CM, Lu C, Corbin KL, Sharma PR, Dula SB, Carter JD, Ramadan JW, Xin W, Lee JK, Nunemaker CS, et al. Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice. Endocrinology. 2013;154(9):3077–3088. doi:10.1210/en.2012-2138.
   PubMed Web of Science ®Google Scholar
• Ohashi A, Uemura Y, Yoshimori M, Wada N, Imadome K-I, Yudo K, Koyama T, Shimizu N, Nishio M, Arai A, et al. The plasma level of interleukin-1β can be a biomarker of angiopathy in systemic chronic active Epstein–Barr virus infection. Front Microbiol. 2022;13:874998. doi:10.3389/fmicb.2022.874998.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, et al. The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100(4):1215–1219. doi:10.1182/blood.V100.4.1215.h81602001215_1215_1219.
   PubMed Web of Science ®Google Scholar
• Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol. 2012;24(3):218–224. doi:10.1016/j.smim.2012.02.005.
   PubMed Web of Science ®Google Scholar
• Kang P, Liu D, Li L, Guo X, Ye Y, Li Y, Jiang Q, Lin S, Yuan Q. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade. Cytokine. 2023;163:156133. doi:10.1016/j.cyto.2023.156133.
   PubMed Web of Science ®Google Scholar
• Borilova Linhartova P, Kavrikova D, Tomandlova M, Poskerova H, Rehka V, Dušek L, Izakovicova Holla L. Differences in interleukin-8 plasma levels between diabetic patients and healthy individuals independently on their periodontal status. Int J Mol Sci. 2018;19(10):3214. doi:10.3390/ijms19103214.
   PubMed Web of Science ®Google Scholar
• Solito S, Pinton L, De Sanctis F, Ugel S, Bronte V, Mandruzzato S, Marigo I. Methods to measure MDSC immune suppressive activity in vitro and in vivo. Curr Protoc Immunol. 2019;124(1):e61. doi:10.1002/cpim.61.
   PubMedGoogle Scholar
• Parks DR, Roederer M, Moore WA. A new “Logicle” display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. Cytometry A. 2006;69(6):541–551. doi:10.1002/cyto.a.20258.
   PubMedGoogle Scholar
• Linderman GC, Rachh M, Hoskins JG, Steinerberger S, Kluger Y. Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. Nat Methods. 2019;16(3):243–245. doi:10.1038/s41592-018-0308-4.
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer. JAMA Oncol. 2018;4(3):351–357. doi:10.1001/jamaoncol.2017.4771.
   PubMed Web of Science ®Google Scholar
• Long H, Jia Q, Wang L, Fang W, Wang Z, Jiang T, Zhou F, Jin Z, Huang J, Zhou L, et al. Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell. 2022;40(6):674–693.e7. doi:10.1016/j.ccell.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, et al. Inhibition of granulocytic myeloid-derived suppressor cells overcomes resistance to immune checkpoint inhibition in LKB1-deficient non–small cell lung cancer. Cancer Res. 2021;81(12):3295–3308. doi:10.1158/0008-5472.CAN-20-3564.
   PubMed Web of Science ®Google Scholar
• Bertelli G, Trovato R, Ugel S, Bria E, Milella M, Bronte V, Pilotto S. Characterization of myeloid-derived suppressor cells in a patient with lung adenocarcinoma Undergoing durvalumab treatment: A case report. Clin Lung Cancer. 2019;20(4):e514–e516. doi:10.1016/j.cllc.2019.04.013.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhao Q, Tan L, Wu X, Huang R, Zuo Y, Chen L, Yang J, Zhang Z-X, Ruan W, et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell. 2023;41(4):693–710.e8. doi:10.1016/j.ccell.2023.03.004.
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel S-E, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40(5):509–523.e6. doi:10.1016/j.ccell.2022.04.004.
   PubMed Web of Science ®Google Scholar
• Li L, Liu YD, Zhan YT, Zhu Y-H, Li Y, Xie D, Guan X-Y. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma. Thorac Cancer. 2018;9(7):775–784. doi:10.1111/1759-7714.12643.
   PubMed Web of Science ®Google Scholar
• Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin GV, Shurin MR, Dinarello CA, Voronov E, Apte RN. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation. Proc Natl Acad Sci USA. 2019;116(4):1361–1369. doi:10.1073/pnas.1812266115.
   PubMed Web of Science ®Google Scholar
• Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M, et al. Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. J Exp Med. 2022;219(6):219 (6. doi:10.1084/jem.20212169.
   PubMed Web of Science ®Google Scholar
• La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, et al. Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res. 2021;81(4):956–967. doi:10.1158/0008-5472.CAN-20-1885.
   PubMed Web of Science ®Google Scholar
• Campesato LF, Budhu S, Tchaicha J, Weng C-H, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11(1):4011. doi:10.1038/s41467-020-17750-z.
   PubMed Web of Science ®Google Scholar
• Serafini M, Torre E, Aprile S, Grosso ED, Gesù A, Griglio A, Colombo G, Travelli C, Paiella S, Adamo A, et al. Discovery of highly potent benzimidazole derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) inhibitors: From structure-based virtual screening to in vivo pharmacodynamic activity. J Med Chem. 2020;63(6):3047–3065. doi:10.1021/acs.jmedchem.9b01809.
   PubMed Web of Science ®Google Scholar
• Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, Rescigno M, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208(10):1949–1962. doi:10.1084/jem.20101956.
   PubMed Web of Science ®Google Scholar
• De Sanctis F, Lamolinara A, Boschi F, Musiu C, Caligola S, Trovato R, Fiore A, Frusteri C, Anselmi C, Poffe O, et al. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. J Immunother Cancer. 2022;10(1):e003549. doi:10.1136/jitc-2021-003549.
   PubMed Web of Science ®Google Scholar
• Vigano S, Alatzoglou D, Irving M, Ménétrier-Caux C, Caux C, Romero P, Coukos G. Targeting Adenosine in cancer immunotherapy to Enhance T-Cell function. Front Immunol. 2019;10:925. doi:10.3389/fimmu.2019.00925.
   PubMed Web of Science ®Google Scholar
• Oh MH, Sun IH, Zhao L, Leone RD, Sun I-M, Xu W, Collins SL, Tam AJ, Blosser RL, Patel CH, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Invest. 2020;130(7):3865–3884. doi:10.1172/JCI131859.
   PubMed Web of Science ®Google Scholar
• Aaboe Jorgensen M, Ugel S, Linder Hubbe M, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, et al. Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with anti–PD-1 checkpoint blockade. Cancer Immunol Res. 2021;9(11):1316–1326. doi:10.1158/2326-6066.CIR-21-0280.
   PubMed Web of Science ®Google Scholar
• Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021;27(12):2212–2223. doi:10.1038/s41591-021-01544-x.
   PubMed Web of Science ®Google Scholar
• Cane S, Barouni RM, Fabbi M, Cuozzo J, Fracasso G, Adamo A, Ugel S, Trovato R, De Sanctis F, Giacca M, et al. Neutralization of NET-associated human ARG1 enhances cancer immunotherapy. Sci Transl Med. 2023;15(687):eabq6221. doi:10.1126/scitranslmed.abq6221.
   PubMed Web of Science ®Google Scholar
• Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, et al. Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade. J Immunother Cancer. 2022;10(6):e004582. doi:10.1136/jitc-2022-004582.
   PubMed Web of Science ®Google Scholar